Chronic Lymphocytic Leukemia Tests
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
Protherics Plc Announces Final Results
Protherics Plc Announces Final Results
Stories of Hope: Teen cancer survivor, family committed to finding a cure
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, May 29th NXPC, XSNX, CIRT, G
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, May 29th NXPC, XSNX, CIRT, G
OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, May 29th NXPC, XSNX, CIRT, G
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Tria
Protherics PLC Announces AGM and Interim Management Statement